Michigan Head Pain and Neurological Institute — Biomedical Watch V2

Essais liés10clinical trials

VilleAnn Arborlocalisation

PaysUnited Stateslocalisation

SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT03832998

Ouvrir le site du centre

Essais cliniques associés

10

Molécule	Indication / population	Phase	NCT	Titre	Statut
Elismetrep (K-304) 2 mg	Migraine	Phase 2	NCT06848075	A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine	COMPLETED
Erenumab Dose 1	Migraine	Phase 3	NCT03832998	OASIS(CM) — Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine	COMPLETED
sumatriptan nasal powder	Migraine	Phase 3	NCT03338920	Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents	TERMINATED
Erenumab	Migraine	Phase 4	NCT04252742	EMBRACE — Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine	COMPLETED
Eptinezumab	Migraine	Phase 3	NCT05897320	PROSPECT-1 — A Study of Eptinezumab in Pediatric Participants With Episodic Migraine	RECRUITING
Erenumab Dose 1	Migraine	Phase 3	NCT03836040	OASIS(EM) — Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine	ACTIVE_NOT_RECRUITING
Eptinezumab	Migraine	Phase 3	NCT05164172	REJOIN — A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine	RECRUITING
Eptinezumab	Migraine	Phase 3	NCT04965675	PROSPECT-2 — A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine	RECRUITING
Rimegepant (PF-07899801)	Migraine	Phase 3	NCT04743141	Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine	RECRUITING
Rimegepant	Migraine	Phase 2/3	NCT03266588	Open Label Safety Study in Acute Treatment of Migraine	COMPLETED